+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Role of advanced glycation end products (AGEs) in osteoporosis in diabetes



Role of advanced glycation end products (AGEs) in osteoporosis in diabetes



Current Drug Targets 12(14): 2096-2102



Recent meta-analyses have revealed that the risk of bone fracture is increased in both type 1 and type 2 diabetic patients. Low bone mineral density (BMD) can not necessarily explain the link, because BMD is increased rather than decreased in type 2 diabetes, while it is consistently low in type 1 diabetes subjects. Although multiple factors could influence the quality of bone and increase the bone fragility in diabetes, there is accumulating evidence for the association between osteoporosis and vascular calcification, which is an independent predictor of cardiovascular disease morbidity and mortality. Advanced glycation end products (AGEs) are formed by a non-enzymatic reaction between aldehydes of reducing sugars and the amino groups of proteins, lipids and nucleic acids that could contribute to the aging of macromolecules. The formation and accumulation of AGEs have been known to progress at an accelerated rate under diabetes. There is a growing body of evidence that AGEs and their receptor (RAGE) system elicit oxidative stress generation and subsequently evoke inflammatory responses in vascular wall cells, osteoblasts and osteoclasts, thereby being involved in both vascular calcification and osteoporosis in diabetes. Further, cross-linking in the organic bone matrix by AGEs could adversely affect the fracture resistance of bone. Therefore, in this paper, I review the pathophysiological role of the AGEs-RAGE-oxidative stress system in decreased BMD and increased bone fragility in diabetes. I also discuss here the potential therapeutic interventions of the AGEs-RAGE axis for preventing osteoporosis in diabetes.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 055600554

Download citation: RISBibTeXText

PMID: 22023404


Related references

Role of Advanced Glycation End Products (Ages) in Osteoporosis in Diabetes. Current Drug Targets 12(14): 2096-2102, 2011

Irbesartan attenuates advanced glycation end products-mediated damage in diabetes-associated osteoporosis through the AGEs/RAGE pathway. Life Sciences 205: 184-192, 2018

Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes. Experimental Gerontology 46(4): 217-224, 2011

New metabolic marker: Advanced glycation end products (AGEs) and receptor for advanced glycation end products (RAGE) system may play a role in the pathogenesis of recurrent pregnancy losses. Journal of Reproductive Immunology 106: 10-11, 2014

Role of Advanced Glycation End Products (Ages) in Thrombogenic Abnormalities in Diabetes. Current Neurovascular Research 3(1): 73-77, 2006

Role of advanced glycation end products (AGEs) in thrombogenic abnormalities in diabetes. Current Neurovascular Research 3(1): 73-77, 2006

Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes. Biochimica et Biophysica Acta 1820(5): 663-671, 2012

The receptor for advanced glycation end-products has a central role in mediating the effects of advanced glycation end-products on the development of vascular disease in diabetes mellitus. Nephrology, Dialysis, Transplantation 11(Suppl. 5): 13-16, 1996

Advanced glycation end-products (AGEs): a novel therapeutic target for osteoporosis in patients with rheumatoid arthritis. Medical Hypotheses 73(2): 201-202, 2009

Critical Appraisal of Advanced Glycation End Products (AGEs) and Circulating Soluble Receptors for Advanced Glycation End Products (sRAGE) as a Predictive Biomarkers for Cardiovascular Disease in Hemodialysis Patients. Medical Sciences 6(2), 2018

The potential role of advanced glycation end products (AGEs) and soluble receptors for AGEs (sRAGE) in the pathogenesis of adult-onset still's disease. Bmc Musculoskeletal Disorders 16: 111, 2016

Advanced Glycation End Products (Ages) and Cardiovascular Disease (Cvd) in Diabetes. Cardiovascular & Hematological Agents in Medicinal Chemistry 5(3): 236-240, 2007

Advanced glycation end products (AGEs) and cardiovascular disease (CVD) in diabetes. Cardiovascular and Hematological Agents in Medicinal Chemistry 5(3): 236-240, 2007

Advanced glycation end products (AGEs), free radicals and diabetes. Journal de la Societe de Biologie 195(4): 387-390, 2002

Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes. Diabetes/Metabolism Research and Reviews 24(2): 109-114, 2007